Fluoxetine (hydrochloride)

Fluoxetine (hydrochloride)

• CAS Number: 56296-78-7
• UNSPSC Description: Fluoxetine hydrochloride (LY 110140) is an antidepressant and a selective serotonin reuptake inhibitor.
• Target Antigen: Autophagy; Serotonin Transporter
• Type: Reference compound
• Related Pathways: Autophagy;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Neurological Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/fluoxetine-hydrochloride.html
• Purity: 99.97
• Solubility: DMSO : ≥ 25 mg/mL|H2O : 8.33 mg/mL (ultrasonic)
• Smiles: FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F.Cl
• Molecular Weight: 345.79
• References & Citations: [1]Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71|[2]Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80.|[3]Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84.|[4]Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61|[5]Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62.|[6]Su WJ, et al. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J Neuroinflammation. 2017 Oct 30;14(1):210.Fundam Clin Pharmacol. 2018 Aug;32(4):363-377.|J Neuroinflammation. 2017 Oct 30;14(1):210.|J Neuroinflammation. 2023 May 10;20(1):112.|Neuropharmacology. 2021 Feb 15;184:108410.|Neurotox Res. 2020 Dec;38(4):887-899.|Preprints. 2023 Dec 27.|Behav Brain Res. 2017 Jan 15;317:62-70. |Behav Pharmacol. 2021 Jan 6.|Behav Pharmacol. 2024 Apr 24.|Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.|Biochem Pharmacol. 2023 Oct 5:115846.|Biomedicines. 2023 Apr 26, 11(5), 1279.|Brain Behav Immun. 2021 Mar 15;S0889-1591(21)00114-8.|Cell Prolif. 2021 Jan;54(1):e12953.|Cell Rep. 2021 Nov 2;37(5):109957.|Chemosphere. 2019 Jun;225:378-387. |Eur J Pharmacol. 2019 Jan 15;843:260-267.|J Clin Psychopharmacol. 2021 Jun 11.|J Psychiatr Res. 2023 Oct 19.|J Transl Med. 2024 Aug 22;22(1):785.|Nat Med. 2019 Sep;25(9):1428-1441.|Orebro University. 2024.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267.|Research Square Preprint. 2023 Jun 16.|Research Square Preprint. 2023 Jun 29.|Virol J. 2024 Aug 8;21(1):181.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched